FI19991730A - Enantiomers of 1 - ((4-chlorophenylmethyl) -4 - ((4-methylphenyl) sulfonyl) piperazine - Google Patents

Enantiomers of 1 - ((4-chlorophenylmethyl) -4 - ((4-methylphenyl) sulfonyl) piperazine

Info

Publication number
FI19991730A
FI19991730A FI991730A FI19991730A FI19991730A FI 19991730 A FI19991730 A FI 19991730A FI 991730 A FI991730 A FI 991730A FI 19991730 A FI19991730 A FI 19991730A FI 19991730 A FI19991730 A FI 19991730A
Authority
FI
Finland
Prior art keywords
ethyl
methylphenyl
enantiomers
chlorophenylmethyl
piperazine
Prior art date
Application number
FI991730A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI105915B (en
Inventor
Guy Bodson
Jean Gobert
Eric Cossement
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of FI19991730A publication Critical patent/FI19991730A/en
Application granted granted Critical
Publication of FI105915B publication Critical patent/FI105915B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

The use of levorotatory or dextrorotatory enantiomers of 1-(4-chlorophenyl)phenylmethylpiperazine derivatives (V) or their salts in medicines for the treatment of allergies, is new. The use of levorotatory or dextrorotatory enantiomers of 1-(4-chlorophenyl)phenylmethylpiperazine derivatives of formula (V) or their salts, in medicines for the treatment of allergies, is new: R = H, (3-methylphenyl)methyl, (4-tert-butylphenyl)methyl, 2-(2-hydroxyethoxy)ethyl, 2-(2-(hydroxyethoxy)ethoxy)ethyl, 2-(carbamoylethoxy)ethyl, 2-(methoxycarbonylmethoxy)ethyl or 2-(carboxymethoxy)ethyl.
FI991730A 1993-03-15 1999-08-16 The process prepares enantiomers of 1 - [(4-chlorophenyl) phenylmethyl] -piperazine FI105915B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9305282 1993-03-15
GB939305282A GB9305282D0 (en) 1993-03-15 1993-03-15 Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine

Publications (2)

Publication Number Publication Date
FI19991730A true FI19991730A (en) 1999-08-16
FI105915B FI105915B (en) 2000-10-31

Family

ID=10732080

Family Applications (3)

Application Number Title Priority Date Filing Date
FI941134A FI105477B (en) 1993-03-15 1994-03-10 Enantiomers of 1 - [(4-chlorophenyl) phenylmethyl] -4 - [(4-methylphenyl) sulfonyl] piperazine and process for their preparation
FI991730A FI105915B (en) 1993-03-15 1999-08-16 The process prepares enantiomers of 1 - [(4-chlorophenyl) phenylmethyl] -piperazine
FI991729A FI105914B (en) 1993-03-15 1999-08-16 The process for the preparation of a pharmaceutically active enantiomer of 1 - [(4-chlorophenyl) phenylmethyl] -4 - [(4-methylphenyl) sulfonyl] piperazine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI941134A FI105477B (en) 1993-03-15 1994-03-10 Enantiomers of 1 - [(4-chlorophenyl) phenylmethyl] -4 - [(4-methylphenyl) sulfonyl] piperazine and process for their preparation

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI991729A FI105914B (en) 1993-03-15 1999-08-16 The process for the preparation of a pharmaceutically active enantiomer of 1 - [(4-chlorophenyl) phenylmethyl] -4 - [(4-methylphenyl) sulfonyl] piperazine

Country Status (24)

Country Link
US (17) US5478941A (en)
EP (3) EP1413307A1 (en)
JP (3) JP3267434B2 (en)
KR (1) KR100322415B1 (en)
AT (2) ATE267185T1 (en)
AU (1) AU678426B2 (en)
CA (2) CA2118859C (en)
DE (2) DE69424893T2 (en)
DK (1) DK0617028T3 (en)
ES (2) ES2221262T3 (en)
FI (3) FI105477B (en)
GB (1) GB9305282D0 (en)
GR (1) GR3034340T3 (en)
HK (1) HK1024232A1 (en)
HU (1) HU219230B (en)
NO (2) NO305908B1 (en)
NZ (1) NZ260062A (en)
PL (1) PL178546B1 (en)
PT (1) PT617028E (en)
RU (1) RU2118320C1 (en)
SG (1) SG43683A1 (en)
SI (2) SI0955295T1 (en)
TW (1) TW237452B (en)
ZA (1) ZA941724B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
ATE177636T1 (en) * 1992-09-24 1999-04-15 Sepracor Inc TRANSDERMAL TREATMENT OF HURTS WITH OPTICALLY PURE (+)-CETIRIZINE
WO1994006429A1 (en) * 1992-09-24 1994-03-31 Sepracor, Inc. Compositions for treating allergic disorders using (-) cetirizine
GB9305282D0 (en) * 1993-03-15 1993-05-05 Ucb Sa Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine
EP0690051B1 (en) * 1994-01-14 2001-07-18 Azwell Inc. Diazacycloalkanealkylsulfonamide derivative
CN1058638C (en) * 1995-06-27 2000-11-22 中国药品生物制品检定所 Extraction of allergen of intracellular Mycobacterium
AU7455798A (en) 1997-06-04 1998-12-21 Nippon Shoji Kaisha, Ltd. Process for producing piperazinesulfonamide derivatives and salts thereof
US6384038B1 (en) 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
IL124195A (en) * 1998-04-23 2000-08-31 Chemagis Ltd Process for the preparation of esters of 2-¬4-¬4-chlorophenyl¾phenylmethyl¾-1-piperazinyl¬ethoxy¾acetic acid
US6432961B1 (en) * 1998-08-18 2002-08-13 Ucb S.A. Method for preventing the onset of asthma
WO2001040211A1 (en) * 1999-11-30 2001-06-07 EGIS Gyógyszergyár Rt. A PROCESS FOR THE PREPARATION OF {2-[4-(α-PHENYL-p-CHLOROBENZYL)PIPERAZIN-1-YL]ETHOXY}ACETIC ACID AND NOVEL INTERMEDIATES THEREFOR
JP2002249487A (en) 2001-02-22 2002-09-06 Sumitomo Chem Co Ltd 4-(tert-butoxycarbonyl)piperazine derivative, optically active acid addition salt of the same, method for producing them and optically active 1-[(substituted phenyl)phenylmethylpiperazine which uses them
US6977301B1 (en) 2001-05-29 2005-12-20 Ucb, S.A. Process for preparing (S) and (R)—2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide
US7199241B1 (en) 2001-05-29 2007-04-03 Ucb, S.A. Process for preparing (S) and (R)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide
CN1692105A (en) * 2002-12-04 2005-11-02 雷迪实验室有限公司 Cetirizine dihydrochloride polymorph and preparation method thereof
EP1620127A4 (en) * 2003-03-20 2007-04-04 Rinat Neuroscience Corp Methods for treating taxol-induced gut disorder
US7577727B2 (en) * 2003-06-27 2009-08-18 Newisys, Inc. Dynamic multiple cluster system reconfiguration
KR100503443B1 (en) 2004-02-02 2005-07-22 한림제약(주) Processes for preparing an optically active cetirizine or its salt
EA012575B1 (en) * 2005-03-03 2009-10-30 Юсб Фархим Са Pyroglutamate salts and their use in the optical resolution of intermediates for the synthesis of dextrocetirizine and levocetirizine
HU227074B1 (en) * 2005-12-08 2010-06-28 Egis Gyogyszergyar Nyrt An optically active carbamic acid derivative, method for producing the same and use as a pharmaceutical intermediate
WO2008110586A2 (en) 2007-03-12 2008-09-18 Krka, Tovarna Zdravil, D.D., Novo Mesto New process for the preparation of levocetirizine and intermediates thereof
WO2008152650A1 (en) 2007-06-15 2008-12-18 Symed Labs Limited Process for preparation of substantially optically pure levorotatory and dextrorotatory enantiomers of cetirizine using novel intermediates
US20090062305A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched cetirizine
US20090082364A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched levocedtirizine
KR101427100B1 (en) 2007-10-23 2014-08-08 주식회사 씨트리 Method for Preparing an Optically Active 1-[(4-chlorophenyl)phenylmethyl] -piperazine
DE602007012725D1 (en) 2007-11-21 2011-04-07 Synthon Bv Process for the preparation of N- (diphenylmethyl) piperazines
US7989623B2 (en) * 2007-11-21 2011-08-02 Synthon Bv Process for making n-(diphenylmethyl)piperazines
KR100954755B1 (en) * 2007-12-17 2010-04-27 한미약품 주식회사 Method for preparing r---1-[4-chloro-phenylphenyl-methyl]piperazine
JP2011523659A (en) * 2008-06-02 2011-08-18 シプラ・リミテッド Method for synthesizing levocetirizine and intermediate used therefor
KR100998067B1 (en) 2008-09-08 2010-12-03 주식회사 삼오제약 A novel Bis1-[4-chlorophenylphenylmethyl]piperazine-2,3-Dibenzoyl tartarate intermediate salt and the method for isolating optically active 1-[4-chlorophenylphenylmethyl]piperazine using thereby
US20100145049A1 (en) * 2008-11-21 2010-06-10 Jie Zhu Process for making n-(diphenylmethyl)piperazines
CN102459210B (en) * 2009-04-22 2015-09-02 埃克希金医药品有限公司 Arylsulfonamide ccr 3 antagonists
CN101928223A (en) * 2009-06-26 2010-12-29 华东理工大学 Resolution method of (R)-(-)-4-chloro benzhydrylamine
WO2012101475A1 (en) 2011-01-27 2012-08-02 Jubilant Life Sciences Limited An improved process for the preparation of antihistaminic drugs via a novel carbamate intermediate
KR101418404B1 (en) 2012-01-06 2014-07-10 한미약품 주식회사 Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
WO2013158318A1 (en) 2012-04-16 2013-10-24 Zemtsov Enterprises, Llc Formulations and methods for treatment of acne and inflammatory skin conditions
CN103613567A (en) * 2012-11-09 2014-03-05 焦作福瑞堂制药有限公司 Synthetic process for chlorcyclizine hydrochloride
KR102226833B1 (en) 2013-06-28 2021-03-12 한미약품 주식회사 Complex granule formulation having improved stability comprising levocetirizine and montelukast
CN104045607B (en) * 2014-05-21 2016-04-13 丽珠医药集团股份有限公司 A kind of purification process of cetrizine hcl
CN111205247B (en) * 2020-04-22 2020-08-14 湖南九典宏阳制药有限公司 Preparation method of levocetirizine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2899436A (en) * 1959-08-11 chjch
BE540057A (en) *
US2709169A (en) * 1955-05-24 X c chs
CA568380A (en) * 1959-01-06 Morren Henri Ethers of piperazine and method of their preparation
BE523901A (en) *
GB752331A (en) * 1948-09-30 1956-07-11 Abbott Lab Improvements in or relating to n, n-disubstituted piperazines and process of preparing the same
US2861072A (en) * 1952-07-19 1958-11-18 Abbott Lab Preparation of piperazine derivatives
US2709167A (en) * 1952-09-10 1955-05-24 Geigy Ag J R Chromium-containing monoazo dyestuffs
US2897436A (en) * 1954-09-29 1959-07-28 Amchem Prod Indicating and control apparatus for electrolyte concentration and the like
US3406174A (en) * 1964-10-23 1968-10-15 Sandoz Ag Benzylsulfamides
DK154078C (en) * 1981-02-06 1989-05-22 Ucb Sa METHOD OF ANALOGUE FOR THE PREPARATION OF 2- (2- (4- (DIPHENYL-METHYL) -1-PIPERAZINYL) ETHOXY) -ACETAMIDES OR ACID ADDITION SALTS.
US4749700A (en) * 1984-10-23 1988-06-07 Nastech Pharmaceutical Co, Inc. Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same
DE3640247A1 (en) * 1986-11-25 1988-05-26 Basf Ag FUNGICIDAL CYCLOHEXYLAMINE
US4975426A (en) * 1987-06-08 1990-12-04 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US5234957A (en) * 1991-02-27 1993-08-10 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
JP2559463B2 (en) * 1988-06-01 1996-12-04 ダイセル化学工業株式会社 Method for optical resolution of compound having two aromatic groups at asymmetric center
JPH0239947A (en) * 1988-07-29 1990-02-08 Seikosha Co Ltd Printing head
GB8827391D0 (en) * 1988-11-23 1988-12-29 Ucb Sa Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride
US4882432A (en) * 1989-01-09 1989-11-21 American Home Products Corporation Polycyclic-carbamic acid piperazinoalkyl esters and amides
US5087627A (en) * 1989-03-15 1992-02-11 Santen Pharmaceutical Co., Ltd. Agent for treatment of disorders of the cerebro-neural transmission system
SG43860A1 (en) * 1990-09-10 1997-11-14 Mitsubishi Electric Corp Coding apparatus
WO1994006429A1 (en) 1992-09-24 1994-03-31 Sepracor, Inc. Compositions for treating allergic disorders using (-) cetirizine
ATE177636T1 (en) 1992-09-24 1999-04-15 Sepracor Inc TRANSDERMAL TREATMENT OF HURTS WITH OPTICALLY PURE (+)-CETIRIZINE
GB9305282D0 (en) * 1993-03-15 1993-05-05 Ucb Sa Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine

Also Published As

Publication number Publication date
CA2118859A1 (en) 1994-09-16
CA2118859C (en) 2004-07-13
GR3034340T3 (en) 2000-12-29
ATE267185T1 (en) 2004-06-15
RU2118320C1 (en) 1998-08-27
US20040122021A1 (en) 2004-06-24
NO306616B1 (en) 1999-11-29
US20030105113A1 (en) 2003-06-05
SI0617028T1 (en) 2000-10-31
KR100322415B1 (en) 2002-06-20
JP2002201187A (en) 2002-07-16
FI941134A (en) 1994-09-16
SG43683A1 (en) 1997-11-14
PL178546B1 (en) 2000-05-31
JP3880842B2 (en) 2007-02-14
ES2221262T3 (en) 2004-12-16
PT617028E (en) 2000-11-30
FI105915B (en) 2000-10-31
US20060252934A1 (en) 2006-11-09
ES2147569T3 (en) 2000-09-16
EP1413307A1 (en) 2004-04-28
ZA941724B (en) 1994-10-13
US20050182070A1 (en) 2005-08-18
DE69433802T2 (en) 2005-05-12
EP0617028B1 (en) 2000-06-14
DE69433802D1 (en) 2004-06-24
US20060229319A1 (en) 2006-10-12
NO990351L (en) 1999-01-26
NZ260062A (en) 1995-09-26
CA2443216C (en) 2007-05-08
JP2006342190A (en) 2006-12-21
FI941134A0 (en) 1994-03-10
DK0617028T3 (en) 2000-09-04
DE69424893T2 (en) 2000-10-12
FI105914B (en) 2000-10-31
US20060229320A1 (en) 2006-10-12
US20030204089A1 (en) 2003-10-30
GB9305282D0 (en) 1993-05-05
FI19991729A (en) 1999-08-16
AU5777194A (en) 1994-09-22
JPH072816A (en) 1995-01-06
FI105477B (en) 2000-08-31
US5792770A (en) 1998-08-11
EP0955295B1 (en) 2004-05-19
EP0955295A1 (en) 1999-11-10
NO940881D0 (en) 1994-03-11
US5478941A (en) 1995-12-26
AU678426B2 (en) 1997-05-29
NO940881L (en) 1994-09-16
SI0955295T1 (en) 2004-10-31
NO990351D0 (en) 1999-01-26
HU9400727D0 (en) 1994-06-28
US5703082A (en) 1997-12-30
CA2443216A1 (en) 1994-09-16
US20050182069A1 (en) 2005-08-18
EP0617028A1 (en) 1994-09-28
JP3267434B2 (en) 2002-03-18
DE69424893D1 (en) 2000-07-20
TW237452B (en) 1995-01-01
US6436942B1 (en) 2002-08-20
HUT70959A (en) 1995-11-28
US20040072845A1 (en) 2004-04-15
ATE193889T1 (en) 2000-06-15
HU219230B (en) 2001-03-28
US20030105112A1 (en) 2003-06-05
US20040122023A1 (en) 2004-06-24
NO305908B1 (en) 1999-08-16
US20070142400A1 (en) 2007-06-21
HK1024232A1 (en) 2000-10-05
US20050176732A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
FI19991730A (en) Enantiomers of 1 - ((4-chlorophenylmethyl) -4 - ((4-methylphenyl) sulfonyl) piperazine
AR016351A1 (en) BETA CRYSTAL FORM OF THE METANSULPHONIC ACID ADDITION SALT OF 4- (4-METHYLPIPERAZIN-1-ILMETIL) -N- [4-METHYL-3- (4-PIRIDIN-3-IL) PIRIMIDIN-2-ILAMINO) PHENYL] BENZAMIDE, PHARMACEUTICAL COMPOSITION, USE OF CRYSTAL FORM FOR THE PREPARATION OF A PHARMACOLOGICAL AGENT, AND PROCESSES FOR PREPARATION
FI935851A0 (en) Antiallergic moss treatment For ophthalmic or nasal Bruk
BR9205811A (en) Heterocyclic derivatives of cyclic amines
CO5271691A1 (en) NEW COMPOUNDS
ATE116312T1 (en) ANTIMIGRAINE ALKOXYPYRIMIDINE DERIVATIVES.
KR950031062A (en) Eye drops for eye drops
ATE117208T1 (en) TREATMENT OF INTRAOCULAR PRESSURE WITH AN OPHTHALMIC SYNERGISTIC COMBINATION.
DK591488D0 (en) 1-ACYL-3-OE4- (2-PYRIMIDINYL) -1-PIPERAZINYLAAPROPAN COMPOUNDS, THEIR USE FOR THE PREPARATION OF AN ANTI-ANXICATIVE MEDICINE AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE
HK1054198A1 (en) Novel use of (R)-(-)-2-Ä5-(4-fluorophenyl)-3-pyridylmethylaminomethylÜ-chromane and its physiologically acceptable salts.
DE3778642D1 (en) THERAPEUTIC FOR TREATMENT OF STOMACH.
RO95572A2 (en) PROCESS FOR THE PREPARATION OF 1,3-OXAZOOLIDIN -2-ONE DERIVATIVES